Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas

European Journal of Endocrinology

Volumn 167, Issue 3, 2012, Pages 327-335

  Athanasoulia, A P ^a   Sievers, C ^a   Ising, M ^a   Brockhaus, A C ^b   Yassouridis, A ^b   Stalla, G K ^a   Uhr, M ^c  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Division of Biostatistics   (Germany)

^c Division of Pharmacokinetics and CSF Analysis   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; GLYCOPROTEIN P;

ABCB1 GENE; ADULT; ADVERSE DRUG REACTION; AGGRESSION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BLOOD BRAIN BARRIER; CASE CONTROL STUDY; COMPULSION; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DRUG BRAIN LEVEL; DRUG INDUCED HEADACHE; DRUG TRANSPORT; FATIGUE; FEMALE; GENE; GENETIC ASSOCIATION; HETEROZYGOTE; HUMAN; LIBIDO; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PATHOLOGICAL GAMBLING; PRIORITY JOURNAL; PROLACTINOMA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; VISUAL HALLUCINATION;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; ERGOLINES; FATIGUE; FEMALE; HEADACHE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; PITUITARY NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROLACTINOMA; TREATMENT OUTCOME;

EID: 84865770447     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-0198     Document Type: Article

References (35)

1. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML & McCutcheon IE. The prevalence of pituitary adenomas: a systematic review. Cancer 2004 101 613-619. (doi:10.1002/ cncr.20412)
2. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA & Wass JA. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2011 96 273- 288. (doi:10.1210/jc.2010-1692)
3. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I & Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. New England Journal of Medicine 1994 331 904-909. (doi:10.1056/NEJM199410063311403)
4. Al-Husaynei AJ, Mahmood IH & Al-Jubori ZS. Comparison of the effects of cabergoline and bromocriptine in women with hyperprolactinemic amenorrhea. Middle East Fertility Society Journal 2008 13 33-38.
5. Deuschl G, Vaitkus A, Fox GC, Roscher T, Schremmer D & Gordin A. Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. Movement Disorders 2007 22 1550-1555. (doi:10.1002/mds.21473)
6. Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF & Montastruc JL. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004 18 733-746. (doi:10.2165/00023210- 200418110-00003)
7. Colao A, di Sarno A, Pivonello R, di Somma C & Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opinion on Investigational Drugs 2002 11 787-800. (doi:10.1517/ 13543784.11.6.787)
8. Falhammar H & Yarker JY. Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Medical Journal of Australia 2009 190 97.
9. Davie M. Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. Journal of Neuropsychiatry and Clinical Neurosciences 2007 19 473-474. (doi:10.1176/appi.neuropsych.19.4.473)
10. Gahr M, Connemann BJ & Schonfeldt-Lecuona CJ. Pathological gambling induced by dopamine agonists. Fortschritte der Neurologie Psychiatrie 2011 79 470-474. (doi:10.1055/s-0031-1281580)
11. Martinkova J, Trejbalova L, Sasikova M, Benetin J & Valkovic P. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clinical Neuropharmacology 2011 34 179-181. (doi:10.1097/WNF.0b013e3182281b2f)
12. Voon V, Fernagut PO,Wickens J, Baunez C, Rodriguez M, Pavon N, Juncos JL, Obeso JA & Bezard E. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurology 2009 8 1140-1149. (doi:10.1016/ S1474-4422(09)70287-X)
13. Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M, Fox S, Lang AE & Miyasaki J. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006 66 1750-1752. (doi:10.1212/01.wnl. 0000218206.20920.4d)
14. Voon V, Thomsen T, Miyasaki JM, de Souza M, Shafro A, Fox SH, Duff-Canning S, Lang AE & Zurowski M. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Archives of Neurology 2007 64 212-216. (doi:10.1001/ archneur.64.2.212)
15. Bostwick JM, Hecksel KA, Stevens SR, Bower JH & Ahlskog JE. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clinic Proceedings 2009 84 310-316.
16. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V,Whetteckey J,Wunderlich GR & Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology 2010 67 589-595. (doi:10.1001/ archneurol.2010.65)
17. Ondo WG & Lai D. Predictors of impulsivity and reward seeking behavior with dopamine agonists. Parkinsonism and Related Disorders 2008 14 28-32. (doi:10.1016/j.parkreldis.2007.05. 006)
18. Dang D, Cunnington D & Swieca J. The emergence of devastating impulse control disorders during dopamine agonist therapy of the restless legs syndrome. Clinical Neuropharmacology 2011 34 66-70.
19. Romigi A, Stanzione P, Marciani MG, Izzi F, Placidi F, Cervellino A, Giacomini P, Brusa L, Grossi K & Pierantozzi M. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study. Journal of Neural Transmission 2006 113 1909-1913. (doi:10.1007/s00702-006-0490-x)
20. Hogl B, Rothdach A, Wetter TC & Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 2003 28 1866-1870. (doi:10.1038/sj. npp.1300250)
21. Placidi F, Izzi F, Romigi A, Stanzione P, Marciani MG, Brusa L, Sperli F, Galati S, Pasqualetti P & Pierantozzi M. Sleep-wake cycle and effects of cabergoline monotherapy in de novo Parkinson's disease patients. An ambulatory polysomnographic study. Journal of Neurology 2008 255 1032-1037. (doi:10.1007/ s00415-008-0836-4)
22. Athanasoulia AP, Ising M, Pfister H, Mantzoros CS, Stalla GK & Sievers C. Distinct dopaminergic personality patterns in patients with prolactinomas: a comparison with nonfunctioning pituitary adenoma patients and age- and gender-matched controls. Neuroendocrinology 2012 In press.
23. Marzolini C, Paus E, Buclin T & Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and Therapeutics 2004 75 13-33. (doi:10.1016/j.clpt.2003.09.012)
24. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, Ising M, Dose T, Ebinger M, Rosenhagen M, Kohli M, Kloiber S, Salyakina D, Bettecken T, Specht M, Putz B, Binder EB, Muller-Myhsok B & Holsboer F. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008 57 203-209. (doi:10.1016/j.neuron.2007.11.017)
25. Porcelli S, Drago A, Fabbri C, Gibiino S, Calati R & Serretti A. Pharmacogenetics of antidepressant response. Journal of Psychiatry and Neuroscience 2011 36 87-113.
26. Kato M, Fukuda T, Serretti A, Wakeno M, Okugawa G, Ikenaga Y, Hosoi Y, Takekita Y, Mandelli L, Azuma J & Kinoshita T. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008 32 398-404. (doi:10.1016/j.pnpbp.2007.09.003)
27. Sievers C, Ising M, Pfister H, Dimopoulou C, Schneider HJ, Roemmler J, Schopohl J & Stalla GK. Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gendermatched controls. European Journal of Endocrinology 2009 160 367-373. (doi:10.1530/EJE-08-0896)
28. Westfall PH & Young SS. Resampling-based Multiple Testing: Examples and Methods for P-value Adjustment New York: Wiley, 1993.
29. Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, Stalla GK & Ghigo E. Hypopituitarism. Lancet 2007 369 1461-1470. (doi:10.1016/S0140-6736(07) 60673-4)
30. Mihaljevic Peles A, Bozina N, Sagud M, Rojnic Kuzman M & Lovric M. MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008 32 1439-1444. (doi:10.1016/j.pnpbp.2008.03.018)
31. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ & Hamilton SP. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR&z.ast;D sample. PLoS ONE 2008 3 e1872. (doi:10.1371/journal.pone.0001872)
32. Laika B, Leucht S & Steimer W. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clinical Chemistry 2006 52 893-895. (doi:10.1373/clinchem.2006. 066605)
33. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M & Brinkmann U. Functional polymorphisms of the human multi-drug- resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. PNAS 2000 97 3473-3478. (doi:10.1073/pnas. 050585397)
34. Nikisch G, Eap CB & Baumann P. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study. Pharmacological Research 2008 58 344-347. (doi:10.1016/j.phrs.2008.09.010)
35. Devault A & Gros P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Molecular and Cellular Biology 1990 10 1652-1663.